The National Institute for Health and Care Excellence

Weekly insulin jab could cut injections from 365 a year to just 52

Hundreds of thousands of people with type 2 diabetes could swap daily insulin injections for a once-a-week jab, following a NICE recommendation.
The National Institute for Health and Care Excellence

NICE Listens: hearing the public’s views on AI in health and care

That is why AI is the right next topic for NICE Listens. The dialogue will explore how people want AI to be used in health ...
National Institute for Health and Care Excellence

Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Dementia: assessment, management and support for people living with dementia and their carers

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living ...
National Institute for Health and Care Excellence

Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment ...
National Institute for Health and Care Excellence

Crohn’s disease: management

This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life. NICE has also produced a ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. Next review: More ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line ...
National Institute for Health and Care Excellence

Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...
National Institute for Health and Care Excellence

12 SQ-Bet SLIT for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen in people 5 years and over

Evidence-based recommendations on 12 standardised quality betula verrucosa pollen sublingual lyophilisate (12 SQ-Bet SLIT; Itulazax) for treating moderate to severe allergic rhinitis or conjunctivitis ...